Webinar by Andrew Sewell
What do T-cells target during successful cancer immunotherapy
Andrew Sewell
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
Our research is based around understanding the basic biology of antigen recognition by human T-cells using novel pipelines for the discovery of new T-cell targets. Current research projects include: Dissection of successful T-cell responses after successful cancer immunotherapy or spontaneous remission; TCR gene transfer therapy (TCR-T); Novel CAR-T technologies; T-cell receptor-optimised peptide skewing or the repertoire of T-cells (TOPSORT); Artificial (non-biologic) T-cell antigens as vaccines; T-cell/TCR-based diagnostics in autoimmune disease; and unconventional (non-HLA-restricted) T-cell responses to infection and tumours.